Luciana Berod

Luciana Berod

Auto-generated profile, based on publicly available information

Luciana Berod

Institute of Molecular Medicine, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany; Research Center for Immunotherapy (FZI), University Medical Center Mainz, Mainz, Germany

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2014 in Nature Medicine
Verified
Journal Article
Closed access
LBLuciana Berod
Luciana Berod
CFChristin Friedrich
Christin Friedrich
ANAmrita Nandan
Amrita Nandan
JFJenny Freitag
Jenny Freitag
SHStefanie Hagemann
Stefanie Hagemann
TSTim Sparwasser
Tim Sparwasser

1 September 2018 in Cell Metabolism
Verified
Journal Article
Closed access
BRBrenda Raud
Brenda Raud
Dominic G. RoyDominic G. Roy
Dominic G. Roy
ADAjit S. Divakaruni
Ajit S. Divakaruni
TTTatyana N. Tarasenko
Tatyana N. Tarasenko
RFRaimo Franke
Raimo Franke
LBLuciana Berod
Luciana Berod

17 April 2018 in Immunological Reviews
Verified
Journal Article
Open access
PDF file
BRBrenda Raud
Brenda Raud
PMPeter J McGuire
Peter J McGuire
RJRussell G Jones
Russell G Jones
TSTim Sparwasser
Tim Sparwasser
LBLuciana Berod
Luciana Berod
Summary: CD8+T cells are key members of the adaptive immune response against infections and cancer. As we discuss in this review, these cells can present diverse metabolic requirements, which have been intensely studied during the past few years. Our current understanding suggests that aerobic glycolysis is a hallmark of activatedCD8+T cells, while naive and memory (Tmem) cells often rely on oxidative phosphorylation, and thus mitochondrial metabolism is a crucial determinant ofCD8+Tmemcell development. Moreover, it has been proposed thatCD8+Tmemcells have a specific requirement for the oxidation of long‐chain fatty acids (LC‐FAO), a process modulated in lymphocytes by the enzymeCPT1A. However, this notion relies heavily on the metabolic analysis of in vitro cultures and on chemical inhibition ofCPT1A. Therefore, we introduce more recent studies using genetic models to demonstrate thatCPT1A‐mediatedLC‐FAOis dispensable for the development ofCD8+T cell memory and protective immunity, and question the use of chemical inhibitors to target this enzyme. We discuss insights obtained from those and other studies analyzing the metabolic characteristics ofCD8+Tmemcells, and emphasize how T cells exhibit flexibility in their choice of metabolic fuel.

1 July 2021 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
LALuís Almeida
Luís Almeida
ADAyesha Dhillon-LaBrooy
Ayesha Dhillon-LaBrooy
GCGuilhermina Carriche
Guilhermina Carriche
LBLuciana Berod
Luciana Berod
TSTim Sparwasser
Tim Sparwasser

21 January 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
MSMarianela C. Serradell
Marianela C. Serradell
LRLucía L. Rupil
Lucía L. Rupil
RMRomán A. Martino
Román A. Martino
César Germán PruccaCésar Germán Prucca
César Germán Prucca
PCPedro G. Carranza
Pedro G. Carranza
HLHugo D. Luján
Hugo D. Luján
Intestinal and free-living protozoa, such as Giardia lamblia, express a dense coat of variant-specific surface proteins (VSPs) on trophozoites that protects the parasite inside the host’s intestine. Here we show that VSPs not only are resistant to proteolytic digestion and extreme pH and temperatures but also stimulate host innate immune responses in a TLR-4 dependent manner. We show that these properties can be exploited to both protect and adjuvant vaccine antigens for oral administration. Chimeric Virus-like Particles (VLPs) decorated with VSPs and expressing model surface antigens, such as influenza virus hemagglutinin (HA) and neuraminidase (NA), are protected from degradation and activate antigen presenting cells in vitro. Orally administered VSP-pseudotyped VLPs, but not plain VLPs, generate robust immune responses that protect mice from influenza infection and HA-expressing tumors. This versatile vaccine platform has the attributes to meet the ultimate challenge of generating safe, stable and efficient oral vaccines.

27 October 2022 in European Journal of Immunology
Verified
Journal Article
Open access
MLManfred B Lutz
Manfred B Lutz
SAShafaqat Ali
Shafaqat Ali
CACindy Audiger
Cindy Audiger
SAStella Eugenie Autenrieth
Stella Eugenie Autenrieth
LBLuciana Berod
Luciana Berod
MZMartin Zenke
Martin Zenke
This article is part of the Dendritic Cell Guidelines article series, which provides a collection of state‐of‐the‐art protocols for the preparation, phenotype analysis by flow cytometry, generation, fluorescence microscopy, and functional characterization of mouse and human dendritic cells (DC) from lymphoid organs and various non‐lymphoid tissues. This article provides protocols with top ticks and pitfalls for preparation and successful generation of mouse and human DC from different cellular sources, such as murine BM and HoxB8 cells, as well as human CD34+ cells from cord blood, BM, and peripheral blood or peripheral blood monocytes. We describe murine cDC1, cDC2, and pDC generation with Flt3L and the generation of BM‐derived DC with GM‐CSF. Protocols for human DC generation focus on CD34+ cell culture on OP9 cell layers for cDC1, cDC2, cDC3, and pDC subset generation and DC generation from peripheral blood monocytes (MoDC). Additional protocols include enrichment of murine DC subsets, CRISPR/Cas9 editing, and clinical grade human DC generation. While all protocols were written by experienced scientists who routinely use them in their work, this article was also peer‐reviewed by leading experts and approved by all co‐authors, making it an essential resource for basic and clinical DC immunologists.